PROFILE 1029:克唑替尼对比化疗一线治疗东亚ALK阳性晚期非小细胞肺癌的III期研究结果
PROFILE 1029是一项开放标签III期随机研究,在东亚ALK阳性晚期非鳞非小细胞肺癌患者中比较一线克唑替尼与含铂化疗。克唑替尼显著延长无进展生存期(HR 0.402,95%CI 0.286-0.565,p<0.001),中位PFS为11.1个月对6.8个月,客观缓解率87.5%对45.6%(p<0.001),患者报告结局亦显著改善,安全性与既往报道一致。
要点
- 克唑替尼一线治疗东亚ALK阳性晚期NSCLC显著优于含铂化疗。
- 中位PFS 11.1个月对6.8个月,HR 0.402(95%CI 0.286-0.565,p<0.001)。
- 客观缓解率87.5%对45.6%(p<0.001),患者报告结局显著改善。
核心结论
- 在东亚ALK阳性晚期非鳞NSCLC患者中,一线克唑替尼较标准含铂化疗显著改善PFS、客观缓解率和患者报告结局,结果与PROFILE 1014一致。
研究设计与样本
- 开放标签III期随机研究(PROFILE 1029),患者1:1随机接受口服克唑替尼250 mg每日两次持续给药(3周周期)或静脉化疗(培美曲塞500 mg/m2联合顺铂75 mg/m2或卡铂AUC 5-6 mg·min/mL),每3周一次最多6周期。
- 主要终点为独立影像学评审确认的PFS。
主要发现
- 克唑替尼显著延长PFS(HR 0.402;95%CI 0.286-0.565;p<0.001),中位PFS为11.1个月对6.8个月。
- 客观缓解率为87.5%(95%CI 79.6-93.2%)对45.6%(95%CI 35.8-55.7%)(p<0.001)。
- 克唑替尼最常见不良事件为转氨酶升高、腹泻和视觉障碍,化疗为白细胞减少、中性粒细胞减少和贫血。
- 克唑替尼组患者报告结局较基线的改善显著优于化疗组。
关键数值与推荐
- PFS:HR 0.402(95%CI 0.286-0.565),p<0.001;中位PFS 11.1个月对6.8个月。
- 客观缓解率:87.5%(95%CI 79.6-93.2%)对45.6%(95%CI 35.8-55.7%),p<0.001。
- 克唑替尼剂量:250 mg口服每日两次,持续给药(3周周期)。
- 化疗方案:培美曲塞500 mg/m2联合顺铂75 mg/m2或卡铂AUC 5-6 mg·min/mL,每3周一次,最多6周期。
临床怎么用
- 东亚ALK阳性晚期非鳞NSCLC患者一线可优先考虑克唑替尼治疗。
- 治疗期间需关注转氨酶升高、腹泻和视觉障碍等克唑替尼相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The phase III randomized PROFILE 1014 study demonstrated superiority of crizotinib to first-line chemotherapy in prolonging progression-free survival (PFS) in previously untreated patients with ALK receptor tyrosine kinase gene (ALK)-positive advanced nonsquamous NSCLC. This result was consistent with that in the smaller subset of East Asian patients in PROFILE 1014. The subsequent study reported here prospectively evaluated crizotinib in a larger East Asian patient population. METHODS: In this open-label phase III study (PROFILE 1029), patients were randomized 1:1 to receive orally administered crizotinib 250 mg twice daily continuously (3-week cycles) or intravenously administered chemotherapy (pemetrexed 500 mg/m2, plus cisplatin 75 mg/m2, or carboplatin [at a dose to produce area under the concentration-time curve of 5-6 mg·min/mL]) every 3 weeks for a maximum of six cycles. PFS confirmed by independent radiology review was the primary end point. RESULTS: Crizotinib significantly prolonged PFS (hazard ratio, 0.402; 95% confidence interval [CI]: 0.286-0.565; p < 0.001). The median PFS was 11.1 months with crizotinib and 6.8 months with chemotherapy. The objective response rate was 87.5% (95% CI: 79.6-93.2%) with crizotinib versus 45.6% (95% CI: 35.8-55.7%) with chemotherapy (p < 0.001). The most common adverse events were increased transaminase levels, diarrhea, and vision disorders with crizotinib and leukopenia, neutropenia, and anemia with chemotherapy. Significantly greater improvements from baseline in patient-reported outcomes were seen in crizotinib-treated versus chemotherapy-treated patients. CONCLUSIONS: First-line crizotinib significantly improved PFS, objective response rate, and patient-reported outcomes compared with standard platinum-based chemotherapy in East Asian patients with ALK-positive advanced NSCLC, which is similar to the results from PROFILE 1014. The safety profiles of crizotinib and chemotherapy were consistent with those previously published.
引用
- Wu YL, Lu S, Lu Y, et al. Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29966800. doi:10.1016/j.jtho.2018.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。